Perlecan heparan sulfate is required for the inhibition of smooth muscle cell proliferation by all-trans-retinoic acid

Journal of Cellular Physiology

Volumn 230, Issue 2, 2015, Pages 482-487

  Tran Lundmark, Karin ^a   Tannenberg, Philip ^a   Rauch, Bernhard H ^b   Ekstrand, Johan ^a   Tran, Phan Kiet ^a   Hedin, Ulf ^a   Kinsella, Michael G ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; PERLECAN; PROTEOHEPARAN SULFATE; RETINOIC ACID; SCLEROPROTEIN;

ANIMAL; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; EXTRACELLULAR MATRIX; METABOLISM; MOUSE; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; MICE; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; TRETINOIN;

EID: 84911192058     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24731     Document Type: Article

References (63)

1. Adams JC, Watt FM. 1993. Regulation of development and differentiation by the extracellular matrix. Development 117:1183-1198.
2. Adatia R, Albini A, Carlone S, Giunciuglio D, Benelli R, Santi L, Noonan DM. 1997. Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann Oncol 8:1257-1261.
3. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. 1999. Perlecan is essential for cartilage and cephalic development. Nat Genet 23:354-358.
4. Axel DI, Frigge A, Dittmann J, Runge H, Spyridopoulos I, Riessen R, Viebahn R, Karsch KR. 2001. All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells. Cardiovasc Res 49:851-862.
5. Baldwin CT, Silbert JE, Humphries DE, Cogburn JN, Smith BD. 1989. Increased proteoglycan synthesis following the differentiation of F9 embryonal carcinoma cells: Formation of a differentiation-specific proteoheparan sulfate. Matrix 9:389-396.
6. Belknap JK, Weiser-Evans MC, Grieshaber SS, Majack RA, Stenmark KR. 1999. Relationship between perlecan and tropoelastin gene expression and cell replication in the developing rat pulmonary vasculature. Am J Respir Cell Mol Biol 20:24-34.
7. Bingley JA, Hayward IP, Campbell JH, Campbell GR. 1998. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg 28:308-318.
8. Chen J, He B, Zheng D, Zhang S, Liu J, Zhu S. 1999. All-trans retinoic acid reduces intimal thickening after balloon angioplasty in atherosclerotic rabbits. Chin Med J (Engl) 112:121-123.
9. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
10. Clowes AW, Karnowsky MJ. 1977. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265:625-626.
11. Cohen IR, Murdoch AD, Naso MF, Marchetti D, Berd D, Iozzo RV. 1994. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 54:5771-5774.
12. Colombo A, Chieffo A. 2007. Drug-eluting stent update 2007: Part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). Circulation 116:1424-1432.
13. Connolly RM, Nguyen NK, Sukumar S. 2013. Molecular pathways: Current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 19:1651-1659.
14. Costell M, Carmona R, Gustafsson E, Gonzalez-Iriarte M, Fassler R, Munoz-Chapuli R. 2002. Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ Res 91:158-164.
15. Dahia PL. 2000. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 7:115-129.
16. DeRose JJ, Jr., Madigan J, Umana JP, Prystowsky JH, Nowygrod R, Oz MC, Todd GJ. 1999. Retinoic acid suppresses intimal hyperplasia and prevents vessel remodeling following arterial injury. Cardiovasc Surg 7:633-639.
17. Ehnman M, Li H, Fredriksson L, Pietras K, Eriksson U. 2009. The uPA/uPAR system regulates the bioavailability of PDGF-DD: Implications for tumour growth. Oncogene 28:534-544.
18. Farb A, Burke AP, Kolodgie FD, Virmani R. 2003. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108:1701-1706.
19. Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, Weiser-Evans MC. 2004. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ Res 94:175-183.
20. Geng YJ, Libby P. 2002. Progression of atheroma: A struggle between death and procreation. Arterioscler Thromb Vasc Biol 22:1370-1380.
21. Hedin U, Roy J, Tran PK. 2004. Control of smooth muscle cell proliferation in vascular disease. Curr Opin Lipidol 15:559-565.
22. Hedin U, Roy J, Tran PK, Lundmark K, Rahman A. 1999. Control of smooth muscle cell proliferation-The role of the basement membrane. Thromb Haemost 82:23-26.
23. Hillebrands JL, Rozing J. 2003. Chronic transplant dysfunction and transplant arteriosclerosis: New insights into underlying mechanisms. Expert Rev Mol Med 5:1-23.
24. Jiang X, Multhaupt H, Chan E, Schaefer L, Schaefer RM, Couchman JR. 2004. Essential contribution of tumor-derived perlecan to epidermal tumor growth and angiogenesis. J Histochem Cytochem 52:1575-1590.
25. Kada N, Suzuki T, Aizawa K, Matsumura T, Ishibashi N, Suzuki N, Takeda N, Munemasa Y, Sawaki D, Ishikawa T, Nagai R. 2007. Acyclic retinoid inhibits neointima formation through retinoic acid receptor beta-induced apoptosis. Arterioscler Thromb Vasc Biol 27:1535-1541.
26. Kato S, Sasaguri Y, Morimatsu M. 1993. Down-regulation in the production of matrix metalloproteinase 1 by human aortic intimal smooth muscle cells. Biochem Mol Biol Int 31:239-248.
27. Kinsella MG, Irvin C, Reidy MA, Wight TN. 2004. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 175:51-57.
28. Kinsella MG, Tran PK, Weiser-Evans MC, Reidy M, Majack RA, Wight TN. 2003. Changes in perlecan expression during vascular injury: Role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol 23:608-614.
29. Kinsella MG, Tsoi CK, Jarvelainen HT, Wight TN. 1997. Selective expression and processing of biglycan during migration of bovine aortic endothelial cells. The role of endogenous basic fibroblast growth factor. J Biol Chem 272:318-325.
30. Kooistra T, Opdenberg JP, Toet K, Hendriks HF, van den Hoogen RM, Emeis JJ. 1991. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb Haemost 65:565-572.
31. Li X, Tsai P, Wieder ED, Kribben A, Van Putten V, Schrier RW, Nemenoff RA. 1994. Vascular smooth muscle cells grown on Matrigel. A model of the contractile phenotype with decreased activation of mitogen-activated protein kinase. J Biol Chem 269:19653-19658.
32. Li X, Zhang L, Yin X, Gao Z, Zhang H, Liu X, Pan X, Li N, Yu Z. 2014. Retinoic acid remodels extracellular matrix (ECM) of cultured human fetal palate mesenchymal cells (hFPMCs) through down-regulation of TGF-beta/Smad signaling. Toxicol Lett 225:208-215.
33. Marchisone C, Del Grosso F, Masiello L, Prat M, Santi L, Noonan DM. 2000. Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan. Pathol Oncol Res 6:10-17.
34. Miano JM, Kelly LA, Artacho CA, Nuckolls TA, Piantedosi R, Blaner WS. 1998. All-Trans-retinoic acid reduces neointimal formation and promotes favorable geometric remodeling of the rat carotid artery after balloon withdrawal injury. Circulation 98:1219-1227.
35. Miano JM, Topouzis S, Majesky MW, Olson EN. 1996. Retinoid receptor expression and all-trans retinoic acid-mediated growth inhibition in vascular smooth muscle cells. Circulation 93:1886-1895.
36. Miller JD, Cummings J, Maresh GA, Walker DG, Castillo GM, Ngo C, Kimata K, Kinsella MG, Wight TN, Snow AD. 1997. Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus. Glia 21:228-243.
37. Neuville P, Yan Z, Gidlof A, Pepper MS, Hansson GK, Gabbiani G, Sirsjo A. 1999. Retinoic acid regulates arterial smooth muscle cell proliferation and phenotypic features in vivo and in vitro through an RARalpha-dependent signaling pathway. Arterioscler Thromb Vasc Biol 19:1430-1436.
38. Newby AC, Zaltsman AB. 2000. Molecular mechanisms in intimal hyperplasia. J Pathol 190:300-309.
39. Noonan DM, Horigan EA, Ledbetter SR, Vogeli G, Sasaki M, Yamada Y, Hassell JR. 1988. Identification of cDNA clones encoding different domains of the basement membrane heparan sulfate proteoglycan. J Biol Chem 263:16379-16387.
40. Paka L, Goldberg IJ, Obunike JC, Choi SY, Saxena U, Goldberg ID, Pillarisetti S. 1999. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth. J Biol Chem 274:36403-36408.
41. Ponten A, Folestad EB, Pietras K, Eriksson U. 2005. Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res 97:1036-1045.
42. Rossi M, Morita H, Sormunen R, Airenne S, Kreivi M, Wang L, Fukai N, Olsen BR, Tryggvason K, Soininen R. 2003. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. Embo J 22:236-245.
43. Sarjeant JM, Rabinovitch M. 2002. Understanding and treating vein graft atherosclerosis. Cardiovasc Pathol 11:263-271.
44. Schonherr E, Hausser HJ. 2000. Extracellular matrix and cytokines: A functional unit. Dev Immunol 7:89-101.
45. Sekiguchi RT, Potter-Perigo S, Braun K, Miller J, Ngo C, Fukuchi K, Wight TN, Kimata K, Snow AD. 1994. Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation. J Neurosci Res 38:670-686.
46. Streb JW, Long X, Lee TH, Sun Q, Kitchen CM, Georger MA, Slivano OJ, Blaner WS, Carr DW, Gelman IH, Miano JM. 2011. Retinoid-induced expression and activity of an immediate early tumor suppressor gene in vascular smooth muscle cells. PLoS ONE 6:e18538.
47. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM. 1999. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 274:20693-20703.
48. Taub M. 1991. Retinoic acid inhibits basement membrane protein biosynthesis while stimulating dome formation by Madin Darby canine kidney cells in hormonally defined serum-free medium. J Cell Physiol 148:211-219.
49. Tran PK, Tran-Lundmark K, Soininen R, Tryggvason K, Thyberg J, Hedin U. 2004. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ Res 94:550-558.
50. Uruno A, Sugawara A, Kudo M, Sato M, Sato K, Ito S, Takeuchi K. 2003. Transcription suppression of thromboxane receptor gene expression by retinoids in vascular smooth muscle cells. Hypertens Res 26:815-821.
51. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. 2001. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276:48627-48630.
52. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. 2000. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20:5010-5018.
53. Virmani R, Farb A. 1999. Pathology of in-stent restenosis. Curr Opin Lipidol 10:499-506.
54. Wakino S, Kintscher U, Kim S, Jackson S, Yin F, Nagpal S, Chandraratna RA, Hsueh WA, Law RE. 2001. Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators. Arterioscler Thromb Vasc Biol 21:746-751.
55. Walker HA, Whitelock JM, Garl PJ, Nemenoff RA, Stenmark KR, Weiser-Evans MC. 2003. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell 14:1941-1952.
56. Wang SY, Gudas LJ. 1988. Protein synthesis inhibitors prevent the induction of laminin B1, collagen IV (alpha 1), and other differentiation-specific mRNAs by retinoic acid in F9 teratocarcinoma cells. J Cell Physiol 136:305-311.
57. Wang SY, LaRosa GJ, Gudas LJ. 1985. Molecular cloning of gene sequences transcriptionally regulated by retinoic acid and dibutyryl cyclic AMP in cultured mouse teratocarcinoma cells. Dev Biol 107:75-86.
58. Weintraub WS. 2007. The pathophysiology and burden of restenosis. Am J Cardiol 100:3K-9K.
59. Weiser MC, Belknap JK, Grieshaber SS, Kinsella MG, Majack RA. 1996. Developmental regulation of perlecan gene expression in aortic smooth muscle cells. Matrix Biol 15:331-340.
60. Weiser MC, Grieshaber NA, Schwartz PE, Majack RA. 1997. Perlecan regulates Oct-1 gene expression in vascular smooth muscle cells. Mol Biol Cell 8:999-1011.
61. Wiegman PJ, Barry WL, McPherson JA, McNamara CA, Gimple LW, Sanders JM, Bishop GG, Powers ER, Ragosta M, Owens GK, Sarembock IJ. 2000. All-trans-retinoic acid limits restenosis after balloon angioplasty in the focally atherosclerotic rabbit: A favorable effect on vessel remodeling. Arterioscler Thromb Vasc Biol 20:89-95.
62. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. 1998. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95:15587-15591.
63. Yamada KM, Araki M. 2001. Tumor suppressor PTEN: Modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114:2375-2382.